The “Personalising Actinic Keratosis Treatment for Immunocompromised Patients” (IM-PAKT) Project: An Expert Panel Opinion-Reference-Cited by-同舟云学术

The “Personalising Actinic Keratosis Treatment for Immunocompromised Patients” (IM-PAKT) Project: An Expert Panel Opinion

Published:2024-06-21 Issue:7 Volume:14 Page:1739-1753
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Szeimies Rolf-Markus^ORCID,Ulrich Claas,Ferrándiz-Pulido Carla,Hofbauer Gunther F. L.,Lear John Thomas,Lebbé Celeste,Piaserico Stefano,Hædersdal Merete

Funder

Galderma

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13555-024-01215-y.pdf

Reference48 articles.

1. Balcere A, Kupfere MR, Čēma I, Krūmiņa A. Prevalence, discontinuation rate, and risk factors for severe local site reactions with topical field treatment options for actinic keratosis of the face and scalp. Medicina (Kaunas). 2019;55:92.

2. Cerio R. The importance of patient-centred care to overcome barriers in the management of actinic keratosis. J Eur Acad Dermatol Venereol. 2017;31:17–20.

3. de Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR. British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis. Br J Dermatol. 2017;176:20–43.

4. Hasan ZU, Ahmed I, Matin RN, et al. Topical treatment of actinic keratoses in organ transplant recipients: A feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments). Br J Dermatol. 2022;187:324–37.

5. Ratushny V, Gober MD, Hick R, Ridky TW, Seykora JT. From keratinocyte to cancer: The pathogenesis and modelling of cutaneous squamous cell carcinoma. J Clin Invest. 2012;122:464–72.